Lentivirus Packaging | Synbio Technologies

Home > Virus Packaging > Lentivirus Packaging

The General Introduction of Lentivirus Packaging

Synbio Technologies has enhanced the safety of HIV-1-derived lentiviral vectors with a third-generation packaging system. These optimized lentiviruses deliver efficient, stable, and reproducible gene expression across all cell types, making them ideal for both dividing and non-dividing cells. We offer comprehensive virus packaging services, including overexpression, RNA interference, sgRNA, and library packaging.

Highlights

Long-lasting & Stable Expression of Target Genes
Enhanced Safety, Resulting in No Pathogenicity
Highly Customizable
Free Control Virus & Polybrene

Service Details

Lentivirus Packaging
Service Types	Titer	Volume	Turnaround Time
RNAi Lentivirus	110⁸ TU/ml or110⁹ TU/ml	1ml	20-25 Business Days
sgRNA Lentivirus	110⁸ TU/ml or110⁹ TU/ml
Overexpression Lentivirus	110⁸ TU/ml or110⁹ TU/ml
Library Series Lentivirus	110⁸ TU/ml or110⁹ TU/ml

QUOTE

Deliverables

Free polybrene

Free control virus

Virus liquid, ≥10⁸ TU/mL, 200 μL/tube

QC report

FAQs

What cell lines are commonly used for lentivirus packaging?

Human embryonic kidney cells (HEK293T cells) are commonly used due to their high transfection efficiency and ability to produce high titers of lentivirus. Other cell lines such as 293FT or 293H are also used.

How should lentiviral particles be stored?

For short-term storage, lentiviral particles can be kept at 4°C for up to a week. For long-term storage, aliquot and freeze at -80°C. Avoid repeated freeze-thaw cycles.

What are the differences between the packaging systems of second and third-generation lentiviral vectors?

Second-generation lentiviral packaging systems use three plasmids, with some viral genes still present. This raises safety concerns due to potential recombination. In contrast, third-generation systems use four plasmids, separating the genes for structural and regulatory proteins into different plasmids. This enhances safety and minimizes the risk of replication-competent viruses. The separation makes third-generation systems safer for research and clinical use while maintaining high efficiency.

More FAQs>>

Challenges and Potential Solutions in Viral Vector ProductionView More

Complexities in Manufacturing Processes
The production of viral vectors presents a multitude of intricate challenges that necessitate attention and sophisticated solutions. A primary obstacle lies in refining the design of vectors to guarantee both safety and efficacy. Each vector must undergo meticulous engineering to execute its function without eliciting detrimental immune responses.

Balancing Yield and Safety
Another pivotal concern involves minimizing immunogenicity, where the immune system reacts adversely to the vector, while simultaneously maximizing its yield. Attaining this delicate balance is indispensable for effective therapeutic applications. Techniques such as advanced genetic engineering and leveraging cutting-edge biotechnologies can aid in refining vector attributes and enhancing overall safety profiles.

Overcoming Scalability and Quality Assurance Hurdles
Scalability poses a significant challenge, particularly due to the intricate concentration and purification processes required for commercial-scale viral vector production. Addressing these hurdles necessitates the implementation of robust, scalable production systems and the enhancement of purification methodologies. Continuous innovation in production processes is crucial to meet stringent quality standards without compromising on scale.

Get in Touch with Us